Literature DB >> 18207313

Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract.

Marco Roscigno1, Cesare Cozzarini, Roberto Bertini, Vincenzo Scattoni, Massimo Freschi, Luigi Filippo Da Pozzo, Alberto Briganti, Andrea Gallina, Umberto Capitanio, Renzo Colombo, Guazzoni Giorgio, Francesco Montorsi, Patrizio Rigatti.   

Abstract

OBJECTIVES: To analyze the prognostic role of lymphadenectomy (LND) in patients with muscle-invasive transitional cell carcinoma (TCC) of the upper urinary tract (UUT) managed with radical surgery.
METHODS: From 1986 to 2003, 132 consecutive patients with muscle-invasive TCC of the UUT underwent radical surgery. LND was performed in 95 cases. Patients were stratified according to the presence of LND and lymph node (LN) status. Univariable and multivariable Cox regression models determined the effect of age, pT, grade, nodal status (pN), number of LNs removed, year of surgery, and postoperative chemotherapy on disease-free survival (DFS) and cancer-specific survival (CSS) in the overall population and in patients who underwent LND.
RESULTS: The actuarial 5-yr CSS in pNx patients was significantly worse than in pN0 patients (48% vs. 73%, p=0.001) and comparable to pN+ outcome (48% vs. 39%, p=0.476). In the entire population, multivariable Cox regression analyses indicated that pT and pN status were independent predictors of DFS (p=0.04, hazard ratio [HR]=1.82 and p<0.01, HR=1.34, respectively) and CSS (p<0.01, HR=2.42 and p=0.04, HR=1.32, respectively). In patients who underwent LND, the number of LNs removed was an independent predictor of DFS (p=0.03, HR=0.928) and of CSS (p=0.007, HR=0.903). The extent of LND again resulted in an independent predictor either of DFS or CSS (p=0.04, HR=0.904 and p=0.01, HR=0.867, respectively) in the subgroup of pN0 patients.
CONCLUSIONS: LND emerged as a strong independent predictor of DFS and CSS in patients surgically managed for a muscle-invasive TCC of the UUT.

Entities:  

Mesh:

Year:  2008        PMID: 18207313     DOI: 10.1016/j.eururo.2008.01.008

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  43 in total

1.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

2.  Canadian guidelines for postoperative surveillance of upper urinary tract urothelial carcinoma.

Authors:  Anil Kapoor; Christopher B Allard; Peter Black; Wassim Kassouf; Christopher Morash; Ricardo Rendon
Journal:  Can Urol Assoc J       Date:  2013 Sep-Oct       Impact factor: 1.862

3.  Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.

Authors:  Piotr Zareba; Barak Rosenzweig; Andrew G Winer; Jonathan A Coleman
Journal:  Cancer       Date:  2017-02-02       Impact factor: 6.860

4.  No overt influence of lymphadenectomy on cancer-specific survival in organ-confined versus locally advanced upper urinary tract urothelial carcinoma undergoing radical nephroureterectomy: a retrospective international, multi-institutional study.

Authors:  Maximilian Burger; Shahrokh F Shariat; Hans-Martin Fritsche; Juan Ignacio Martinez-Salamanca; Kazumasa Matsumoto; Thomas F Chromecki; Vincenzo Ficarra; Wassim Kassouf; Christian Seitz; Armin Pycha; Stefan Tritschler; Thomas J Walton; Giacomo Novara
Journal:  World J Urol       Date:  2011-06-01       Impact factor: 4.226

5.  Lymph node dissection could bring survival benefits to patients diagnosed with clinically node-negative upper urinary tract urothelial cancer: a population-based, propensity score-matched study.

Authors:  Fan Dong; Tianyuan Xu; Xianjin Wang; Yifan Shen; Xiaohua Zhang; Shanwen Chen; Shan Zhong; Minguang Zhang; Qiang Ding
Journal:  Int J Clin Oncol       Date:  2018-10-17       Impact factor: 3.402

6.  Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma.

Authors:  Eiji Kikuchi; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Shuji Mikami; Yair Lotan; Mesut Remzi; Christian Bolenz; Cord Langner; Alon Weizer; Francesco Montorsi; Karim Bensalah; Theresa M Koppie; Mario I Fernández; Jay D Raman; Wassim Kassouf; Christopher G Wood; Nazareno Suardi; Mototsugu Oya; Shahrokh F Shariat
Journal:  J Clin Oncol       Date:  2008-12-15       Impact factor: 44.544

7.  The impact of lymph node status and features on oncological outcomes in urothelial carcinoma of the upper urinary tract (UTUC) treated by nephroureterectomy.

Authors:  Adil Ouzzane; Pierre Colin; Tarek P Ghoneim; Marc Zerbib; Alexandre De La Taille; François Audenet; Fabien Saint; Nicolas Hoarau; Emilie Adam; Marie Dominique Azemar; Henri Bensadoun; Luc Cormier; Olivier Cussenot; Alain Houlgatte; Gilles Karsenty; Charlotte Maurin; François Xavier Nouhaud; Véronique Phe; Thomas Polguer; Mathieu Roumiguié; Alain Ruffion; Morgan Rouprêt
Journal:  World J Urol       Date:  2012-12-11       Impact factor: 4.226

8.  Current Status of Lymphadenectomy During Radical Nephroureterectomy for Upper Tract Urothelial Cancer-Yes, No or Maybe?

Authors:  Ashwin Sunil Tamhankar; Saurabh Ramesh Patil; Puneet Ahluwalia; Gagan Gautam
Journal:  Indian J Surg Oncol       Date:  2018-08-13

9.  Comprehensive management of upper tract urothelial carcinoma.

Authors:  Georgios Koukourakis; Georgios Zacharias; Michael Koukourakis; Kiriaki Pistevou-Gobaki; Christos Papaloukas; Athanasios Kostakopoulos; Vassilios Kouloulias
Journal:  Adv Urol       Date:  2008-12-10

10.  Retroperitoneal lymph nodes in transitional cell carcinoma of the kidney and ureter.

Authors:  Shilajit D Kundu; Scott E Eggener
Journal:  Adv Urol       Date:  2009-01-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.